Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease

Levodopa (l-dopa) remains the most effective drug in the treatment of Parkinson's disease (PD). However, l-dopa-induced dyskinesia (LID) has hindered its use for PD patients. The mechanisms of LID are not fully understood. Substance P (SP) receptor antagonist has been shown to reduce parkinsoni...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Experimental neurology 2015-09, Vol.271, p.168-174
Hauptverfasser:	Yang, Xinxin, Zhao, Hui, Shi, Hongjuan, Wang, Xiaoying, Zhang, Shenyang, Zhang, Zunsheng, Zu, Jie, Zhang, Wei, Shen, Xia, Cui, Guiyun, Hua, Fang
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenergic Agents - toxicity Animals Antiparkinson Agents - adverse effects Apomorphine - pharmacology Disease Models, Animal Dopamine Dopamine - metabolism Dopamine Agonists - pharmacology Drug Administration Schedule Dyskinesia, Drug-Induced - drug therapy Gene Expression Regulation - drug effects Indoles - therapeutic use Levodopa - adverse effects Levodopa induced dyskinesia Male MAP Kinase Signaling System - drug effects Motor Activity - drug effects Neurokinin 1 receptor Neurokinin-1 Receptor Antagonists - therapeutic use Oxidopamine - toxicity Parkinson Disease - drug therapy Parkinson Disease - etiology Parkinson Disease - pathology Parkinson's disease Piperidines - therapeutic use Protein kinase A Rats Rats, Sprague-Dawley Substance P Substantia Nigra - drug effects Substantia Nigra - metabolism Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!